Received 18 October 1999/Returned for modification 22 November
1999/Accepted 6 December 1999
 |
INTRODUCTION |
The upper airway rapidly becomes
colonized with bacteria after birth. Although the majority of members
of the normal flora are nonpathogenic, potential pathogens such as
Streptococcus pneumoniae and Moraxella
catarrhalis initiate colonization early in life in a manner
similar to nonpathogens and continue to colonize the host
throughout childhood. By 6 months of age, more than one-third of
children will have been colonized with S. pneumoniae and
more than one-half will have been colonized with M. catarrhalis (10). Between 6 and 12 months of life,
approximately one-fourth of children will be colonized monthly
with one or both of these pathogens (10). Typically,
the pathogens remain in the airway for several months before
disappearing or are replaced by a different strain of the same pathogen
(1, 13, 18, 22). The host factors responsible for
elimination of the pathogen are not well understood. However,
experience with another airway pathogen, nontypeable Haemophilus
influenzae, suggests that the local immune response may play a
role in controlling the trafficking of the organisms (9,
14).
Pneumococcal surface protein A (PspA) and the high-molecular-weight
protein of the outer membrane of M. catarrhalis (UspA) were
selected as target antigens for immunologic study because they are both
potential vaccine candidates. The plan of this study was to determine
whether these antigens were recognized as immunogens in young children
and whether the magnitude or presence of the response correlated with
known information about the colonization status of the children.
 |
MATERIALS AND METHODS |
Study populations.
In 1990, we initiated a prospective study
of nasopharyngeal colonization and otitis media. Children were enrolled
at birth and monitored through the age of 2 years. They were examined
monthly from 1 to 6 months of age and then at 8, 10, 12, 15, 18, 21, and 24 months. At each of these visits, a nasopharyngeal culture was obtained. Middle ear pathogens such as S. pneumoniae,
M. catarrhalis and nontypeable H. influenzae were
identified in the culture (10). Because the original study
was designed to focus on the local immune response to nontypeable
H. influenzae, nasopharyngeal secretions (NPS) were
collected 1 month after the initial colonization with nontypeable
H. influenzae for antibody determinations (14). Thus, the NPS may have been collected before, during, or after colonization with S. pneumoniae and M. catarrhalis. Thirty children represent the study group in this
report. Seventeen of the children were colonized with either S. pneumoniae or M. catarrhalis prior to the collection of
NPS; 13 children were not colonized.
Three adults with chronic lung disease were also selected for study.
They were part of a large prospective study being conducted by T. Murphy and associates at the Veterans Administration Hospital in
Buffalo, N.Y. The adults were examined monthly after entry into the
study. At each visit, sputum samples were collected. Potential
pathogens such as S. pneumoniae, M. catarrhalis,
and nontypeable H. influenzae were identified in culture.
A total of 80 children and 10 adults provided blood samples for serum
antibody determinations. The children had been monitored prospectively
from the age of 2 months through 5 years as part of a poliovirus
vaccine trial (8). A pool of sera from 10 children was
prepared at 2, 4, and 5 months and 1, 2, 3, 4, and 5 years. A pool of
sera from 10 normal adults was also prepared.
Preparation of NPS, sputa, and sera for antibody
determinations.
NPS were aspirated via a soft plastic catheter
into a trap. A 1-ml volume of saline was aspirated through the catheter
to remove residual secretions. The secretions were delivered to the laboratory on ice. The secretions were centrifuged at 2,000 rpm for 10 min to remove large particles. The supernatants were filtered through a
0.45-µm-pore-size filter. The filtrates were frozen at
70°C until
assayed for antibody. Sputa were processed in a similar manner except
for the use of saline. Sera were separated from whole blood by
centrifuging for 10 minutes at 2,000 rpm. The sera was frozen at
70°C until assayed for antibody. Ten sera were pooled for antibody
determinations for each age group.
Antigens for the enzyme-linked immunosorbent assay (ELISA).
The PspA from S. pneumoniae strain Rx1 was used for this
study. Recombinant Rx1 PspA was purified by nickel affinity
chromotography from a cloned gene product which includes amino acids 1 to 303 of the mature PspA protein and is 37 kDa long (29).
Rx1 PspA is a representative member of one of two major families of
PspA molecules. UspA of M. catarrhalis came from strain
25240 (17). The UspA preparation produced a band with a
molecular mass of approximately 400 kDa on sodium dodecyl
sulfate-polyacrylamide gel electrophoresis with Coomassie blue staining.
Procedure for ELISA.
The wells in a 96-well microtiter plate
(Immulon 1B; Dynex Technologies, Chantilly, Va.) were coated overnight
at room temperature with 100 µl of M. catarrhalis UspA
containing 0.25 µg of protein per ml in carbonate-bicarbonate coating
buffer (pH 9.6) or 100 µl of S. pneumoniae PspA containing
1 µg of protein per ml. The wells were washed three times with
phosphate-buffered saline (PBS) (pH 7.2)-0.05% Tween 20. NPS,
sputa, and sera were similarly diluted in PBS-0.05% Tween 20-1%
bovine serum albumin and added to the wells in 100-µl volumes. The
plates were incubated at room temperature for 2 h. Preliminary
studies demonstrated that 2 h of incubation was optimal. At the
same time, a microtiter plate for immunoglobulin standards was
prepared. The wells were coated with rabbit anti-human immunoglobulin G
(IgG) (1:10,000), rabbit anti-human IgM (1:5,000), or rabbit anti-human
IgA (1:20,000) (Dako Corp., Santa Barbara, Calif.) in
carbonate-bicarbonate coating buffer and incubated overnight at room
temperature. The wells were washed three times with PBS-0.05% Tween
20. Portions (100 µl) of decreasing concentrations of pure human IgG,
IgM, or IgA, starting with 0.85, 0.29, and 0.25 µg/ml, respectively,
were added, and the wells were incubated at room temperature for 2 h. The wells were washed three times in PBS-0.05% Tween 20. Horseradish peroxidase-conjugated rabbit anti-human IgG (1:10,000), IgM
(1:5,000), or IgA (1:20,000) were added to the wells (100 µl per
well), and the wells were incubated for 1 h at 37°C. The wells
were washed three times in PBS-0.05% Tween 20 before 100 µl of
o-phenylenediamine dihydrochloride (OPD; Sigma Chemical Co.,
St. Louis, Mo.), prepared in citrate buffer (pH 5.0), was added at 1 µg/ml. The OPD was incubated for 30 min in the dark. The reaction was
stopped by adding 75 µl of 1 N H2SO4 to each
well. Antibody concentrations were calculated from the standard
isotypic immunoglobulin curve and expressed as micrograms or nanograms
of antibody per milliliter.
The optimal concentrations of UspA and PspA needed to coat the wells
were determined in premilinary studies by conducting dose-response
experiments. The optimal concentrations of anti-human IgG, IgM, and IgA
reagents were determined by checkerboard analysis. Preliminary studies
with hypogammaglobulinemic sera demonstrated the specificity of the
ELISA reactions. Two normal adults provided NPS, prepared in the same
manner as for the samples from the children, as positive controls for
the NPS assays with young children. A pool of NPS from 50 children
younger than 1 year in the original study group was also used as a
positive control for subsequent NPS assays to ensure the stability of
IgA stored in our freezer for >8 years. These controls demonstrated
detectable levels of total and specific IgA but low or no detectable
levels of total and specific IgG or IgM. The sensitivity of the IgG,
IgM, and IgA assays were 1, 5, and 5 ng/ml, respectively.
Statistics.
All comparasions between two groups were
assessed by the Mann-Whitney U test for independent samples. Less than
5 ng of IgM and IgA per ml and less than 1 ng of IgG per ml were
assigned the value 0. The results are presented as
P values. All statistical tests were based on a significant
value of P < 0.05.
 |
RESULTS |
Serum antibody.
The age groups selected for study were
children of 2, 4, and 5 months and 1, 2, 3, 4, and 5 years and adults
between 20 and 60 years. Total levels of IgG, IgM, and IgA in serum as
well as specific antibody concentrations of PspA of S. pneumoniae and UspA of M. catarrhalis in serum were
determined. As seen in Fig. 1a and b, IgG
was the dominant antibody class of specific antibody detected, followed
by IgM. Interestingly, there was little if any IgG antibody response
until 2 years of age, even though the total IgG concentrations rose
rapidly in the first 2 years (Fig. 2).
The pattern of specific IgG antibody differed between the two
pathogens. The response to PspA was more robust and peaked during
childhood. Levels of PspA IgG antibody in adults declined to levels
seen at 36 months. In contrast, the UspA IgG antibody level rose more
gradually and peaked in adulthood. These patterns were corroborated
when the specific antibody was represented as a proportion of total IgG
(Fig. 1c and d). The IgM response to both pathogens in serum
represented a higher proportion of the total corresponding
immunoglobulin than either IgG or IgA specific antibody, and the
proportion peaked between 36 and 48 months. IgA antibody levels to both
antigens in serum remained relatively low throughout life, varying
between undetectable at 2 months for M. catarrhalis to a
high of 2,735 ng/ml for PspA at 5 years.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 1.
Antibody to PspA of S. pneumoniae and UspA of
M. catarrhalis in serum according to age. (a) PspA-specific
antibody; (b) UspA-specific antibody; (c) PspA-specific antibody/total
antibody; (d) UspA specific antibody/total antibody. , IgG; ,
IgM; , IgA.
|
|
Mucosal antibody.
IgG, IgM, and IgA antibody responses to PspA
and UspA were first measured in the NPS of two normal adults. Only
IgA-specific antibody was detected. Based on this observation, as well
as on our previous experience with mucosal immunity to nontypeable
H. influenzae (14), we measured the IgA response
exclusively in NPS from 30 infants. These children had been monitored
prospectively from birth through the first year of life. Each child was
examined at nine monthly scheduled visits. At each visit a
nasopharyngeal culture was obtained. Colonization with either S. pneumoniae or M. catarrhalis was documented and
recorded according to the age of the child. As seen in Table
1, seven children were colonized with
S. pneumoniae before NPS were collected for antibody
determinations. The mean age at the time of antibody determination was
6.1 months. NPS were collected 1 month after S. pneumoniae
colonization in three children, 2 months after colonization in three
children, and 4 months after colonization in one child. Even though
total IgA was detected in the NPS of all children, only two NPS samples had any measurable antigen specific antibody (9 and 18 ng/ml). Each of
the seven children were colonized on more than one occasion. Six of the
seven children were colonized after the NPS collection, and these
included the two children with antigen-specific mucosal IgA antibody.
Eight children who had not been colonized prior to NPS collection were
also studied. They were similar in age to the colonized group. Four of
the noncolonized children became colonized after the NPS collection.
One of these children had 5 µg of antigen-specific mucosal antibody
per ml detected at 4.5 months of age even though NPS cultures at 1 to 4 months of age were negative for S. pneumoniae, suggesting
prior undetected colonization.
Ten children were colonized with M. catarrhalis before
collection of NPS for antibody determinations (Table
2). The mean age at the time of
antibody determination was 6.1 months. NPS were collected 1 month
after colonization in one child, 2 months after colonization in three
children, 4 months after colonization in three children, and 5 months
after colonization in one child. Three children were colonized at the
time of NPS collection, but all of them had been colonized previously.
Even though total mucosal IgA was detected in the secretions of all
children, none of the samples had measurable antigen-specific antibody.
Of the 10 children, 8 were colonized after the NPS collection.
Five children who had not been colonized prior to NPS collection were
studied also. Their mean age was 4.4 months, significantly
younger than the control group. The concentration of total mucosal IgA
in the NPS of noncolonized children was significantly lower than that
in the colonized group (P = 0.008). This may reflect
the age difference in the two groups. None of these children had
detectable antigen-specific antibody.
Because of the failure to detect significant numbers of colonized
children with antigen-specific mucosal antibody, we next examined sputa
from three adults with chronic lung disease. One of them had been
colonized with S. pneumoniae 1, 7, and 8 months before
sputum collection (Table 3). Each of them
had been colonized with M. catarrhalis; one had been
colonized 2 months before sputum collection, one had been colonized 10 months before sputum collection, and one had been colonized 3 months
before sputum collection. IgA-specific mucosal antibody to PspA was
detected in all three specimens. The highest concentration was detected
in subject 3, who had been colonized prior to sputum collection.
IgA-specific mucosal antibody to the UspA of M. catarrhalis
was detected in all three specimens.
View this table:
[in this window]
[in a new window]
|
TABLE 3.
IgA antibody to PspA of S. pneumoniae and UspA
of M. catarrhalis in sputa of adults with chronic
obstructive lung disease
|
|
 |
DISCUSSION |
Although both S. pneumoniae and M. catarrhalis are currently considered airway pathogens, S. pneumoniae has been recognized as a major respiratory pathogen for
100 years whereas M. catarrhalis has been recognized as a
major respiratory pathogen only during the past 30 years
(7). The amount of information about the pneumococcus,
associated disease, and immunity has increased substantially. A number
of recent publications described the importance of S. pneumoniae PspA in both disease production and immunity. For
example, PspA is attached to the surface of the pneumococcus by the
C-terminal end of the molecule, and much of the immune response
elicited by immunization in animals is directed against the N-terminal
-helical portion of the molecule (20). The
pspA gene is expressed in all strains of pneumococci,
regardless of their capsular serotype (5). Antibody
responses to PspA in animals protect against sepsis and nasopharyngeal
colonization (25, 26). Although PspA is a heterogenous
protein, there is a high degree of serologic cross-reactivity among
different PspA molecules from the two major families of PspA (2,
23). A single recombinant PspA protein is capable of inducing
protection against pneumococcal strains of diverse capsular serotypes
and different PspA serotypes in animal models (2, 19).
Thus, it is hypothesized that a single PspA protein may be able
to provide protection against multiple diverse strains of
S. pneumoniae (2, 25).
In 1988, Bartos and Murphy (1) first demonstrated the
homogeneity of the outer membrane proteins of a diverse group of M. catarrhalis strains. A high-molecular-weight protein,
UspA, in the outer membrane was subsequently identified, purified, and found to be a target for protective antibodies (15, 17). The protein varies between 300 and 720 kDa (15, 17) and is found in all strains of M. catarrhalis. UspA contains highly
conserved as well as variable surface-exposed epitopes (3).
The conserved epitopes are immunogenic and elicit functional
antibodies. Convalescent-phase sera from adults with M. catarrhalis pneumonia contain antibody to the protein
(15). Antibody to the protein enhances pulmonary clearance
of the organism in an animal model. We chose to study the immune
response to the UspA in young children and secondarily in the general population.
The serological survey of sera in the general population in the present
study clearly demonstrated a predominance of IgG antibodies to S. pneumoniae and M. catarrhalis. Although the
concentration of PspA IgG antibody was slightly higher than that of
UspA IgG antibody early in life, the concentrations of both types
of antibody remained low till after the age of 2 years. A decline
in PspA IgG antibody concentration was noted in sera from adults, and this was reflected in a similar decline in the proportion of total IgG
represented by PspA-specific IgG. This pattern was observed previously
with nontypeable H. influenzae but to a lesser degree (28). In contrast, the level of M. catarrhalis
UspA IgG antibody peaked during adulthood. This pattern has been
observed recently in another study of M. catarrhalis
(4). The reason for the age-related difference between the
organisms is unclear, since colonization with any of the pathogens is
relatively uncommon among adults (6, 16, 24).
The slow induction of an IgG antibody response to the antigens,
especially UspA, in serum early in life may relate to the type of IgG
subclass specific antibodies stimulated. For example, Goldblatt et al.
(12) demonstrated that IgG3 antibodies recognized all of the
outer membrane proteins displayed by M. catarrhalis while
IgG1, IgG2, and IgG4 recognized only the 82- and 60-kDa proteins.
Children younger than 4 years exhibited no detectable IgG3 specific
antibody to M. catarrhalis in their study, and thus their immune systems would not have detected antibody to UspA. Chen et
al. (4) confirmed the relatively poor IgG3 specific antibody
response to M. catarrhalis UspA in children younger than 4 years. In contrast to the importance of an IgG3 response to M. catarrhalis, IgG1 proved to be the major antibody subclass response to nontypeable H. influenzae in children younger
than 4 years, thus explaining the frequent detection of anti-H.
influenzae antibody in young children (27). Little or
no information is available about the IgG subclass responses to PspA
because immunologic studies of the pneumococcus have focused on the
responses to capsular polysaccharide antigens (21).
Only 2 of 7 children colonized with S. pneumoniae and 0 of
10 children colonized with M. catarrhalis in the present
study had detectable specific IgA antibodies in NPS, even
though NPS were collected at the time of colonization as well as
from 1 to 5 months after colonization. These results differ from
those observed with nontypeable H. influenzae, since
every young child colonized with nontypeable H. influenzae developed antigen-specific IgA antibody in NPS
(14). Children who generated a good local antibody response
to H. influenzae tended to decrease or
eliminate subsequent colonization with nontypeable H. influenzae (9, 14). NPS had been processed similarly in
each of these studies; thus, dilution with saline at the time of
collection does not explain the differences observed in detectable
specific antibody. In addition, the levels of total IgA antibody
detected in the NPS were consistent with the levels expected in young
children, affirming the stability of the immunoglobulin during storage
at
70°C. The less robust response to the two immunogens in the
present study could be interpreted in several ways. First, for PspA,
some of the response might have been missed due to the diversity of the
PspA molecule and the nature of our ELISA screening procedure. Only a
recombinant PspA was used to coat the ELISA plates; this was a family 1 PspA protein. Some colonizations may have occurred with strains
containing a heterogeneous PspA protein from family 2. Although
cross-reactivity occurs between all PspA molecules in high-titer sera,
the low titers of the response in children coupled with the diversity of coating antigen and eliciting antigen may have lowered the detection
limits of our assay. The detection of specific mucosal IgA antibodies
in one of the "control" samples in which no colonization had been
detected suggests that undetected colonization may have occurred in
that child. Thus, in at least some children, local responses to PspA
might follow initial colonization and the colonization itself may be of
short duration. It is also possible that capsular antibody plays a role
in limiting colonization of S. pneumoniae. For example, in
mice, immunization with capsular polysaccharide-tetanus toxoid
conjugate reduces but does not eliminate colonization (25). In humans, immunization with a polysaccharide-protein conjugate vaccine
reduces but does not eliminate colonization even with homologous types
(29). In a similar manner, antibody to PspA probably aids in
preventing or reducing colonization but is not the only factor.
Epidemiologic studies with both S. pneumoniae and M. catarrhalis indicate that acquisition of the strain and length of
colonization decrease with increasing age, suggesting that maturation
of the immune system in some way plays a role in controlling
colonization patterns (11, 13). The results of this study
suggest that both PspA and UspA are recognized as immunogens in an
age-dependent manner. The data also suggest that a single episode of
colonization does not induce a strong mucosal response to these two antigens.
We thank Timothy Murphy for providing adult sputa as well as
clinical information about the subjects in his prospective study of
chronic obstructive lung disease. We thank Judith Wolf for technical assistance.
| 1.
|
Bartos, L. C., and T. F. Murphy.
1988.
Comparison of the outer membrane proteins of 50 strains of Branhamella catarrhalis.
J. Infect. Dis.
158:761-766[Medline].
|
| 2.
|
Briles, D. E.,
R. C. Tart,
E. Swiatlo,
J. P. Dillard,
P. Smith,
K. A. Benton,
B. A. Ralph,
A. Brooks-Walter,
M. J. Crain,
S. K. Hollingshead, and L. S. McDaniel.
1998.
Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA).
Clin. Microbiol. Rev.
11:645-657[Abstract/Free Full Text].
|
| 3.
|
Chen, D.,
J. C. McMichael,
K. R. VanDerMeid,
D. Hahn,
T. Mininni,
J. Cowell, and J. Eldridge.
1996.
Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization.
Infect. Immun.
64:1900-1905[Abstract].
|
| 4.
|
Chen, D.,
V. Barniak,
K. R. VanDerMeid, and J. C. McMichael.
1999.
The levels and bactericidal capacity of antibodies directed against the UspA1 and UspA2 outer membrane proteins of Moraxella (Branhamella) catarrhalis in adults and children.
Infect. Immun.
67:1310-1316[Abstract/Free Full Text].
|
| 5.
|
Crain, M. J.,
W. D. Waltman II,
J. S. Turner,
J. Yother,
D. F. Talkington,
L. S. Mcdaniel,
B. M. Gray, and D. E. Briles.
1990.
Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae.
Infect. Immun.
58:3293-3299[Abstract/Free Full Text].
|
| 6.
|
Ejlertsen, T.
1990.
Pharyngeal carriage of Moraxella (Branhamella) catarrhalis in healthy adults.
Eur. J. Clin. Microbiol. Infect. Dis.
10:89.
|
| 7.
|
Faden, H.
1997.
Otitis media, p. 211-227.
In
S. Long, L. Pickering, and C. Prober (ed.), Principles and practice of pediatric infectious diseases. Churchill Livingstone, Inc., New York, N.Y.
|
| 8.
|
Faden, H.,
J. F. Modlin,
M. L. Thomas,
A. M. McBean,
M. B. Ferdon, and P. L. Ogra.
1990.
Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses.
J. Infect. Dis.
162:1291-1297[Medline].
|
| 9.
|
Faden, H.,
L. Duffy,
A. Williams,
D. A. Krystofik, and J. Wolf.
1995.
Epidemiology of nasopharyngeal colonization with nontypeable Haemophilus influenzae in the first 2 years of life.
J. Infect. Dis.
172:132-135[Medline].
|
| 10.
|
Faden, H.,
L. Duffy,
R. Wasielewski,
J. Wolf,
D. Krystofik, and Y. Tung.
1997.
Relationship between nasopharyngeal colonization and the development of otitis media in children.
J. Infect. Dis.
175:1440-1445[Medline].
|
| 11.
|
Faden, H.,
Y. Harabuchi, and J. J. Hong.
1994.
Epidemiology of Moraxella catarrhalis in children during the first 2 years of life: relationship to otitis media.
J. Infect. Dis.
169:1307-1312.
|
| 12.
|
Goldblatt, D.,
M. W. Turner, and R. J. Levinsky.
1990.
Branhamella catarrhalis: antigenic determinants and the development of the IgG subclass response in childhood.
J. Infect. Dis.
162:1128-1135[Medline].
|
| 13.
|
Gray, B. M.,
G. M. Concerse III, and H. C. Dillon, Jr.
1980.
Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life.
J. Infect. Dis.
142:923-933[Medline].
|
| 14.
|
Harabuchi, Y.,
H. Faden,
N. Yamanaka,
L. Duffy,
J. Wolf,
D. Krystofik, and T. W. Pediatrics.
1994.
Nasopharyngeal colonization with nontypeable Haemophilus influenzae and recurrent otitis media.
J. Infect. Dis.
170:862-866[Medline].
|
| 15.
|
Helminen, M. F.,
I. Maciver,
J. L. Latimer,
J. Klesney-Tait,
L. D. Cope,
M. Paris,
G. H. McCracken, Jr., and E. Hansen.
1994.
A large, antigenically conserved protein on the surface of Moraxella catarrhalis is a target for protective antibodies.
J. Infect. Dis.
170:867-872[Medline].
|
| 16.
|
Hendley, J. O.,
M. A. Sande,
P. M. Stewart, and J. M. Gwaltney, Jr.
1975.
Spread of Streptococcus pneumoniae in families. I. Carriage rates and distribution of types.
J. Infect. Dis.
132:55-62[Medline].
|
| 17.
|
Klingman, K. L., and T. F. Murphy.
1994.
Purification and characterization of a high-molecular-weight outer membrane protein of Moraxella (Branhamella) catarrhalis.
Infect. Immun.
62:1150-1155[Abstract/Free Full Text].
|
| 18.
|
Loda, F. A.,
A. M. Collier,
W. P. Glezen,
K. Strangert,
W. A. Clyde, Jr., and F. W. Denny.
1975.
Occurrence of Diplococcus pneumoniae in the upper respiratory tract of children.
J. Pediatr.
87:1087-1093[CrossRef][Medline].
|
| 19.
|
McDaniel, L. S.,
D. O. McDaniel,
S. K. Hollingshead, and D. E. Briles.
1998.
Comparison of the PspA sequence from Streptococcus pneumoniae EF5668 to the previously identified PspA sequence from strain Rx1 and ability of PspA from EF5668 to elicit protection against pneumococci of different capsular types.
Infect. Immun.
66:4748-4754[Abstract/Free Full Text].
|
| 20.
|
McDaniel, L. S.,
J. S. Sheffield,
E. Swiatlo,
J. Yother,
M. J. Crain, and D. E. Briles.
1992.
Molecular localization of variable and conserved regions of PspA and identification of additional PspA homologous sequences in Streptococcus pneumoniae.
Microb. Pathog.
13:261-269[CrossRef][Medline].
|
| 21.
|
Musher, D. M.,
M. J. Luchi,
D. A. Watson,
R. Hamilton, and R. E. Baughn.
1990.
Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide.
J. Infect. Dis.
161:728-735[Medline].
|
| 22.
|
Sluijter, M.,
H. Faden,
R. D. Groot,
N. Lemmens,
W. H. F. Goessens,
A. V. Belkum, and P. W. M. Hermans.
1998.
Molecular characterization of pneumococcal nasopharynx isolates collected from children during their first 2 years of life.
J. Clin. Microbiol.
36:2248-2253[Abstract/Free Full Text].
|
| 23.
|
Talkington, D. F.,
D. C. Voellinger,
L. S. McDaniels, and D. E. Briles.
1992.
Analysis of pneumococcal PspA microheterogeneity is SDS polyacrylamide gels and the association of PspA with the cell membrane.
Microb. Pathog.
13:343-355[CrossRef][Medline].
|
| 24.
|
Vaneechoutte, M.,
G. Verschraegen,
G. Claeys,
B. Weise, and A. M. Van Den Abeele.
1990.
Respiratory tract carrier rates of Moraxella (Branhamella) catarrhalis in adult and children and interpretation of the isolation of M. catarrhalis from sputum.
J. Clin. Microbiol.
28:2674-2680[Abstract/Free Full Text].
|
| 25.
|
Wu, H.-Y.,
M. H. Nahm,
Y. Guo,
M. W. Russel, and D. E. Briles.
1997.
Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae.
J. Infect. Dis.
175:839-846[Medline].
|
| 26.
|
Yamamoto, M.,
L. S. McDaniel,
K. Kawabata,
D. E. Briles,
R. J. Jackson,
J. R. McGhee, and H. Kiyono.
1977.
Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection.
Infect. Immun.
65:640-644[Abstract].
|
| 27.
|
Yamanaka, N., and H. Faden.
1994.
Immune response to P6 of nontypeable Haemophilus influenzae in otitis-prone children with special reference to IgG subclass, p. 27-32.
In
I. Honjo (ed.), The auditory system. Proceedings of the Satellite Symposium of the Second Extraordinary International Symposium on Recent Advances in Otitis Media. Kugler Publications, Amsterdam, The Netherlands.
|
| 28.
|
Yamanaka, N., and H. Faden.
1993.
Antibody response to outer membrane protein of nontypeable Haemophilus influenzae in otitis-prone children.
J. Pediatr.
93:212-218.
|
| 29.
|
Yother, J.,
G. L. Handsome, and D. Briles.
1992.
Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning the pspA gene.
J. Bacteriol.
174:610-618[Abstract/Free Full Text].
|